4/9
08:34 am
cing
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) [Yahoo! Finance]
Low
Report
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) [Yahoo! Finance]
4/9
08:00 am
cing
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
Medium
Report
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
4/3
08:00 am
cing
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
Low
Report
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
3/26
05:00 pm
cing
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Medium
Report
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
3/6
08:12 am
cing
Cingulate Inc. (NASDAQ: CING) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Cingulate Inc. (NASDAQ: CING) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
3/4
09:08 am
cing
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025 [Yahoo! Finance]
Medium
Report
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025 [Yahoo! Finance]
3/4
09:00 am
cing
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
High
Report
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
1/30
08:18 am
cing
Cingulate Inc. (NASDAQ: CING) had its price target raised by analysts at HC Wainwright from $8.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
Cingulate Inc. (NASDAQ: CING) had its price target raised by analysts at HC Wainwright from $8.00 to $20.00. They now have a "buy" rating on the stock.
4/15
05:00 pm
cing
Form PRE 14A Cingulate Inc. For: Apr 15
Medium
Report
Form PRE 14A Cingulate Inc. For: Apr 15
4/9
08:14 am
cing
Form 8-K Cingulate Inc. For: Apr 08
Low
Report
Form 8-K Cingulate Inc. For: Apr 08
3/27
05:13 pm
cing
Form 10-K Cingulate Inc. For: Dec 31
Low
Report
Form 10-K Cingulate Inc. For: Dec 31
3/26
09:06 am
cing
Form 8-K Cingulate Inc. For: Mar 26
Medium
Report
Form 8-K Cingulate Inc. For: Mar 26
3/4
09:06 am
cing
Form 8-K Cingulate Inc. For: Mar 04
Low
Report
Form 8-K Cingulate Inc. For: Mar 04
2/20
06:00 pm
cing
Form 4 Cingulate Inc. For: Feb 18 Filed by: Silva Raul R.
Medium
Report
Form 4 Cingulate Inc. For: Feb 18 Filed by: Silva Raul R.
2/20
06:00 pm
cing
Form 4 Cingulate Inc. For: Feb 18 Filed by: Callahan Jennifer L.
Medium
Report
Form 4 Cingulate Inc. For: Feb 18 Filed by: Callahan Jennifer L.
2/20
06:00 pm
cing
Form 4 Cingulate Inc. For: Feb 18 Filed by: Brams Matthew
Medium
Report
Form 4 Cingulate Inc. For: Feb 18 Filed by: Brams Matthew
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register